The Illumina-backed microbial technology producer will list on the Nasdaq Capital Market through the reverse takeover transaction.
Ginkgo Bioworks, a US-based microbe engineering services provider that counts genomics technology producer Illumina as an investor, agreed to a reverse merger with special purpose acquisition company Soaring Eagle Acquisition Corp today.
The deal values the combined business at $17.5bn and includes a $775m private investment in public equity (PIPE) financing co-led by Baillie Gifford, Putnam Investments and Morgan Stanley Investment Management’s Counterpoint Global vehicle.
The PIPE consortium includes accounts advised by Ark Investment Management as well as ArrowMark Partners,…
